基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
<b>Background: </b>COVID-19 produced by SARS-CoV-2 infection has spread worldwide. There is a growing need for immunological assays to detect viral specific antibodies or viral antigen. Current standard of diagnosis is reverse-transcriptase polymerase chain reaction (RT-PCR) in nasopharyngeal swabs. However serological tests can be used to determine previous exposure to the virus and complement the diagnosis. IgM and IgG SARS-CoV-2 specific antibodies can be detected as early as one week after infection and assays can be useful to test large groups of individuals. This work revised the available information concerning assays that detect antibodies and antigens for SARS-CoV-2. <b>Methods:</b> Three sources of information were used: technical data sheets (TDS) web pages of the company’s products and published articles in Pubmed with reference to the use of diagnostic kits. All the information was revised until April 5<sup>th</sup> 2020. <b>Results: </b>There were 226 tests coming from 20 countries mainly from China. TDS were found only in 50 (22.1%). Most assays detect specific antibodies (n 180) based on immunochromatography methods (n 110) and use blood-derived samples (n 105). Assays for antibodies detection measured mainly IgM/IgG (n 112) and the most common procedure time was <20 min (n 83). Internal control referred as sensitivity and specificity was found only in 18.6% (n 42) of the assays. The majority of the tests are currently for<i> in vitro</i> diagnosis (IVD). A total 165 articles were found on PubMed 15 were included and only 4 used the commercial kits reviewed. <b>Conclusions: </b>Due to the urgency of producing diagnostic tests for SARS-CoV-2 there is a broad offer of kits. Many tests need additional information for their application. The data collected may be useful in the selection of assays but more and higher quality information is needed.
推荐文章
SARS-CoV-2变异株的遗传学特征和致病特点
SARS病毒
遗传变异
突变
毒力
新型冠状病毒
奥密克戎
合理防治SARS-CoV-2感染的思考
传染病
感染病
COVID-19
预防
治疗
合理
新型冠状病毒SARS-CoV-2感染治疗中的“老药新用”
新型冠状病毒
SARS-CoV-2
抗病毒药物
临床药物
老药新用
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 Analysis of Commercial Assays for the Detection of SARS-CoV-2 Antibodies or Antigens
来源期刊 免疫学期刊(英文) 学科 医学
关键词 Antibody ANTIGEN CORONAVIRUS IMMUNOASSAY SARS
年,卷(期) 2020,(2) 所属期刊栏目
研究方向 页码范围 21-35
页数 15页 分类号 R73
字数 语种
DOI
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (0)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
2020(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
研究主题发展历程
节点文献
Antibody
ANTIGEN
CORONAVIRUS
IMMUNOASSAY
SARS
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
免疫学期刊(英文)
季刊
2162-450X
武汉市江夏区汤逊湖北路38号光谷总部空间
出版文献量(篇)
3
总下载数(次)
0
总被引数(次)
0
论文1v1指导